首页> 外文期刊>Applied cancer research. >Increasing evidence for the presence of alternative proteins in human tissues and cell lines
【24h】

Increasing evidence for the presence of alternative proteins in human tissues and cell lines

机译:人体组织和细胞系中存在替代蛋白质的证据越来越多

获取原文
       

摘要

Recent findings coming from human proteome research employing mass-spectrometry and ribosomal profiling methods have provided evidence for the translation of non-annotated coding sequence (CDSs) into alternative proteins (APs). The presence of APs in many human tissues and cell lines may become an important issue in genome sciences, especially in cancer genomics where the frequency of alternative proteins seems to be 10-fold higher than normal tissues. Finding new proteins can impact medical research by filling gaps in known molecular pathways or revealing new molecular markers and therapeutic targets. Among the cellular processes possibly involved in protein diversity, alternative splicing (AS) is the most cited, and it consists of an often-regulated mechanism that generates different mRNAs from the same gene, contributing to the functional diversity of mammalian cells. In the past, evidence for AS from multi-exon genes have come mainly from expression sequence tag (EST) data; only recently has mass-spectrometry (MS) been used to investigate the translation of alternative transcripts. Exploration of human MS data has detected tens to hundreds of alternative proteins in normal tissues, and thousands in cancer cell lines, suggesting that alternative proteins may have an important role in cancer.Analysis of MS data has revealed a vastly diverse AP repertoire, with some of this diversity being exclusively detected in cancer cells. Proteomic characterization of 20 breast cancer cell lines revealed a surprising 1,860 protein variants resulting from AS. Among these, 4 AP are clearly involved in cancer. A truncated variant of the NF- kB p65 subunit, a truncated form of the focal adhesion kinase PTK2 and two CD47 transmembrane receptor protein variants. Until now, little is known about the functional differences between these variants. Another cellular mechanism that possibly creates protein diversity is the alternative usage of translation initiation site (TIS). Detection of TIS is made possible by the Ribosome Profiling (RP) method. The principle of this technique is to capture mRNA translation by freezing the actively translating ribosomes onto transcripts, and then separating them by ultracentrifugation. Recently, RP was applied to mouse embryonic fibroblast cells and human HEK293 cells. The results revealed that the majority of mRNAs contain more than one translation initiation site (TIS), with more than 50% of the detected TISs mapping to alternative ORFs. In this review, we present a list of human alternative proteins validated by small and large-scale experimental methods. We also highlight that APs are probably not a secondary product of inaccurate splicing or translational process and most likely play an important role in the tumorigenic process. Thus, APs constitutes a promising research line for basic and clinical aspects of cancer.
机译:使用蛋白质组学和核糖体谱分析方法进行的人类蛋白质组学研究的最新发现为将非注释编码序列(CDS)转换为替代蛋白(AP)提供了证据。在许多人类组织和细胞系中,AP的存在可能成为基因组科学中的一个重要问题,尤其是在癌症基因组学中,替代蛋白质的频率似乎比正常组织高10倍。寻找新蛋白质可以通过填补已知分子途径中的空白或揭示新的分子标志物和治疗靶点来影响医学研究。在可能涉及蛋白质多样性的细胞过程中,引用最多的是可变剪接(AS),它由经常调节的机制组成,该机制从同一基因产生不同的mRNA,从而促进了哺乳动物细胞的功能多样性。过去,来自多外显子基因的AS证据主要来自表达序列标签(EST)数据。直到最近,质谱(MS)才被用于研究替代转录本的翻译。对人类MS数据的探索已经在正常组织中检测到数十种至数百种替代蛋白,在癌细胞系中检测到数千种,这表明替代蛋白可能在癌症中发挥着重要作用.MS数据的分析显示,AP的种类繁多,其中一些这种多样性的一部分仅在癌细胞中被检测到。 20种乳腺癌细胞系的蛋白质组学表征揭示了AS产生的1,860个令人惊讶的蛋白质变体。其中,4个AP显然与癌症有关。 NF-κBp65亚基的截短变体,粘着斑激酶PTK2的截短形式和两个CD47跨膜受体蛋白变体。到目前为止,对这些变体之间的功能差异知之甚少。可能产生蛋白质多样性的另一种细胞机制是翻译起始位点(TIS)的替代用法。通过核糖体分析(RP)方法可以检测TIS。该技术的原理是通过将主动翻译的核糖体冷冻到转录本上,然后通过超速离心分离它们来捕获mRNA翻译。最近,RP被应用于小鼠胚胎成纤维细胞和人HEK293细胞。结果显示,大多数mRNA都包含一个以上的翻译起始位点(TIS),其中50%以上的检测到的TIS映射到其他ORF。在这篇综述中,我们提出了通过小规模和大规模实验方法验证的人类替代蛋白的列表。我们还强调指出,AP可能不是错误的剪接或翻译过程的次要产物,并且很可能在致瘤过程中起重要作用。因此,AP构成了针对癌症的基础和临床方面的有前途的研究线。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号